Innovation Today, Rewards Tomorrow - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovation Today, Rewards Tomorrow
When it comes to healthcare rform, we must not overlook investment in innovative technologies.


Pharmaceutical Technology
Volume 34, Issue 2, pp. 97-98

America's biopharmaceutical companies are working to find ways to help make the drug- development process more efficient, less costly, and less risky while also supporting initiatives that complement these efforts. For example, several public-private initiatives could increase the efficiency of drug development and approval. Many of these initiatives fall under FDA's Critical Path Initiative.

What it all boils down to is, that if we really want to revolutionalize the way healthcare is consumed and delivered in America today, and continue our world leadership in innovation, we must be honest about whether we want to create a new generation of thinkers and problem-solvers by investing more in education. We must be honest about whether we want to cure diseases and create advanced technologies that improve the length and quality of life.

One of the greatest modern day scientists, Dean Kamen, once said that it is important that we think of every technology made as a gift from one generation to the next. While these products may be expensive now because of the hefty R&D costs, they will be essentially free for our kids because they will go off patent.

The reality is that such innovation is a gift that can keep on giving but only if we continue to celebrate and reward advancements made in science and technology.

If we want to do what is right for the future of our healthcare, we need a full understanding of all the promise that medical progress has to offer. We must recognize the potential of new discoveries and improvements in science and technology as a way to meet many of the great challenges that lay before us today and tomorrow.

Billy Tauzin is president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), tel. 202.835.3400.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here